Have you considered the role of nebulization in COPD maintenance therapy?
Nebulizers: a user-friendly option for COPD patients2
YUPELRI® (revefenacin) inhalation solution delivers a full 24 hours of efficacy in a single daily dose
YUPELRI delivers consistent control over 12 weeks.*
YUPELRI demonstrated consistent improvement in trough FEV1 vs placebo over the 12-week study period.1,11†*In Study 1, LS mean change from baseline in trough FEV1 on day 85 was 127 mL (YUPELRI, n=189) and -19 mL (placebo, n=191), with a statistically significant difference vs placebo of 146 mL (P<.0001). In Study 2, LS mean change from baseline in trough FEV1 on day 85 was 102 mL (YUPELRI, n=181) and -45 mL (placebo, n=187), with a statistically significant difference of 147 mL (P<.0001).11 †The first measurement was taken at 2 weeks.
YUPELRI is covered for up to 100% of patients with Medicare Part B.* J-CODE J7677 Learn More
*This is not a guarantee of coverage. Site of Care will determine coverage. Check with your patient’s insurance provider for coverage rules and restrictions. In certain limited instances, YUPELRI may be covered through a patient’s Medicare Part D pharmacy benefit.